CHRISTOPHER HOLLOMAN: Open Payments
NPI 1639316078 · GOLDSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$513 in 21 payments from 9 companies in 2025. Trend: 2023 $412 · 2024 $1,262 · 2025 $513
Food & beverage: $513
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $156 |
| Neurocrine BioSciences, Inc. | 2 | $79 |
| GlaxoSmithKline, LLC. | 4 | $68 |
| Lilly USA, LLC | 3 | $57 |
| PFIZER INC. | 3 | $50 |
| AstraZeneca Pharmaceuticals LP | 3 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| ABBVIE INC. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
Products named: Ozempic, INGREZZA, TRELEGY ELLIPTA, JARDIANCE, ELIQUIS, PAXLOVID, ZEPBOUND, MOUNJARO.
Industry payments across NC — which companies pay providers there.
